Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HPV16-E7 Other HLA TCR-T
- Development stage
- Unknown
- Lead developer
- National Cancer Institute
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
HPV16-E7 Other HLA TCR-T is an autologous T-cell receptor engineered T-cell (TCR-T) therapy being developed by Anocca. The therapy utilizes T cells engineered to express specific T-cell receptors that recognize peptides derived from the Human Papillomavirus type 16 (HPV16) E7 oncoprotein presented on various Human Leukocyte Antigen (HLA) alleles. By targeting 'other' HLA restrictions beyond the common A*02:01 allele, this program aims to broaden the applicability of TCR-T therapy to a more diverse patient population suffering from HPV-related malignancies, such as cervical and oropharyngeal cancers. The drug is currently in Phase 1 clinical development.
- Other names
- Anocca HPV16 E7 TCR-T (Other HLA)HPV16 E7 TCR-THPV-16 E7 TCR-THPV 16 E7 TCR-T
02
Targets
HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)
Beyond the preview
Go deeper on HPV16-E7 Other HLA TCR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HPV16-E7 Other HLA TCR-T.